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ABSTRACT
Capetola, Robert J., David A. Shriver and Marvin E. Rosen- other hyperalgesic assays, suprofen is an extremely potent
thale: Suprofen, a new peripheral analgesic. J. Pharmacol. inhibitor of arachidonate-induced writhing and is equipotent to
Exp. Ther. 214: 1 6-23, 1 980. morphine in the yeast-induced paw edema (Randall-Selitto)
assay. Additionally, suprofen is inactive on the normal paw in
The antinociceptive properties of suprofen [a-methyl-4-(thien- the Randall-Selitto test, the mouse Eddy hot-plate test and the
ylcarbonyl)benzene acetic acid] are described in a pathologi- tail withdrawal reflex assay induced by warm water in rats, all
cally induced hyperalgesic model, the rat adjuvant arthritic sensitive tests capable of detecting central (narcotic) but not
flexion test. By using this assay, suprofen was characterized peripheral analgesics. Activity on prostaglandin biosynthesis
as an orally effective, non-narcotic analgesic with a rapid onset from several species and tissues suggests that suprofen is a
and 4-hr duration of activity. Suprofen is 50 times more potent tissue selective inhibitor of prostaglandin synthesis. These
than acetaminophen, five times more potent than codeine and experiments suggest that suprofen represents a new class of
equipotent to the new peripheral analgesics, zomepirac and potent, orally effective, peripheral (non-narcotic) analgesics
diflunisal. In combination experiments, suprofen potentiates with potential usefulness in a variety of clinical pain situations
the analgesic effects of acetaminophen and, unlike morphine, formerly reserved for narcotics.
the analgesic effect of suprofen is not blocked by naloxone. In .
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Analgesics can be broadly classified as acting centrally (nar-
cotic) or peripherally (non-narcotic). The centrally acting an-
algesics are very effective in a variety of clinical situations but,
in addition to relieving pain, cause an array of side effects that
limit their clinical utility. The peripherally acting analgesics
also have anti-inflammatory, antipyretic and antithrombotic
properties. This class of agents has been developed in the past
decade primarily for the purpose of improving anti-inflamma-
tory activity and have generally been classified as nonsteroidal
anti-inflammatory drugs (NSAID). With the greater clinical
exposure of these newer anti-inflammatory compounds, more
attention has been given to their analgesic action. Recent
clinical testing has demonstrated these newer agents to be not
only more potent than some of the narcotic analgesics, but, in
certain clinical situations, more efficacious (Smith et a!., 1975;
Bloomfield et a!., 1976; Cooper and Beaver, 1976; Cooper and
Sullivan, 1978). This fmding has stimulated a search to find
new, safer and more effective peripherally acting agents capable
of relieving pain.
This report will describe the analgesic profile of suprofen
(Janssen, 1975; McGuire et a!., 1978), a new, potent, orally
effective non-narcotic analgesic agent in a model of pathological
Received for publication September 24, 1979.
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Toxicology, University of Houston, TX, August 13-17, 1978.
pain and will discuss its differential activity on prostaglandin
biosynthesis. The structure of suprofen is shown in figure 1.
Methods
Analgesic activity in the rat adjuvant arthritic flexion test.
Polyarthritis was induced in male Wistar Lewis rats (150-200 g) by the
injection (0.1 ml) of an autoclaved suspension ofMycobacterium butyr-
icum (0.75 mg, Difco Laboratories, Detroit, MI) in Fruend’s incomplete
adjuvant. The injections were made in the subplantar tissue of the left
hindpaw or into the distal third portion of the tail. Seventeen days
later, the rats were tested for their tendency to vocalize after flexion of
the tarso-tibial joint of the noninjected paw (Kuzuna and Kawai, 1975,
Capetola et a!., 1978) or both paws in the case of the tail-injected
animals. Only those rats that clearly vocalized five successive times at
approximately 3-sec intervals were accepted into the test group. Rats
with ankylosed tarso-tibial joints were rejected.
The rats were fasted for 18 to 24 hr. On day 18 (18 days after
injection of adjuvant) test drugs were administered by gavage and at
various times after administration of drug, usually 1, 2, 3, 4 and 5 hr)
the number of vocalizations were recorded after five fiexions of the
tarso-tibial joint. The data are presented in either oftwo formats: mean
number of vocalizations in the group or in all or none criterion such
that if a rat vocalized three times or more it was considered nonanal-
gesic, two times or less, it was considered analgesic. Animals received
the appropriate drug dose in 5 nil/kg.
Analgesic activity in the yeast-induced paw edema test. A
modification of the method of Randall and Selitto (1957) was used.
Male Sprague-Dawley rats (Charles River Laboratories, Inc., Wilming-
ton, MA) weighing 200 to 300 g were fasted for 18 to 24 hr with water
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cC -Methyl--4-(2 -thienylcarbonyl)
benzene acetic acid
Fig. 1 . Chemical structure of suprofen.
ad libitum. Grams of pressure tolerated by both hindpaws were deter-
mined with a Ugo Basile analgesic meter (with one additional 70 g
weight disc added). Rats tolerating 200 or more grams after three trials
were eliminated from the test. One-tenth milliliter of a 20% suspension
of brewer’s yeast was injected into the subplantar tissue of the left
hindpaw and 2 hr later compounds were administered (5 nil/kg) by
appropriate routes. One hour after administration of compound or
vehicle (0.5% methylcellulose), the pressure tolerated by both hindpaws
was measured and the values recorded.
Arachidonic acid writhing. Male Charles River CD1 mice weigh-
lag 16 to 23 g were divided into groups (N = 10) and placed individually
into Plexiglas observation arenas (2.5 X 5.5 X 3.5 inch). The mice
(fasted at least 16 hr) were dosed orally with a suspension of drug or
0.5% methylcellulose vehicle. One hour later, 1 mg/kg of arachidonic
acid (dissolved in 0.9% saline and titrated to pH 7.4 with 0.1 N NaOH
and then peroxidized by aeration for 5 min) was administered i.p. The
fmal product was termed arachidonic acid peroxide (AAP). Mice were
observed from 2 to 15 min after administration of AAP for the presence
of writhing.
Data were reported as all or none (number of mice writhing per
number of mice treated) in vehicle and respective treatment groups.
Treatment groups were compared with the control group by x2 analysis
by using the Yates Correction. ID,o values for each drug treatment
were estimated by using the linear portion of the dose-response curve
(Finney, 1964).
Renal blood flow in the dog. Renal blood was monitored in the
dog by a modification of the method described by Williamson et al.,
1978. Briefly, adult mongrel dogs of either sex (8-24 kg) were anesthe-
tized with pentobarbital sodium (35 mg/kg i.v.) and surgically prepared
for electromagnetic measurement of renal blood flow. The flow probe
(Carolina Medical Electronics) was placed around the left renal artery
at the site of branching from the abdominal aorta. The right femoral
artery was cannulated to monitor arterial blood pressure and the right
femoral vein was cannulated to administer drugs. Heart rate was
continuously monitored by a cardiotachometer throughout the experi-
ment. All recordings were made on a Beckman dynograph.
Arachidonic acid cascade. Cyclo-oxygenase activity was assayed
in isolated perfused rabbit heart and kidney, prostacyclin synthetase
activity from bovine aorta microsomes, thromboxane synthet.ase activ-
ity from human platelet plasma and anti-prostaglandin E2 (PGE2) or
PGH2 receptor activity on strips ofrabbit aorta, bovine coronary artery,
rat fundus and chicken rectum (P. Needleman, personal communica-
tion). Cyclo-oxygenase activity from bovine seminal vesicles was as-
sayed according to the method of White and Glassman (1974).
Compounds used. The authors would like to thank the following
organizations for their generous supply of compounds: acetaminophen
and zomepirac Na (McNeil Laboratories, Inc., Fort Washington, PA);
sulindac (Clinoril), diflunisal and codeine phosphate (Merck Sharp and
Dohme, West Point, PA); proquazone (Sandoz Pharmaceuticals, Han-
over; NJ); ibuprofen (Motrin; The Upjohn Company, Kalamazoo, MI);
d-propoxyphene (Darvon) and morphine sulfate (Eli Lilly and Corn-
pany, Indianapolis, IN); naloxone (Narcan; Endo Laboratories, Inc.,
Garden City, NY); pentazocine (Talwin; Sterling-Winthrop Research
Institute, Rensselaer, NY); suprofen (Janssen Pharmaceutica, Beerse,
Belgium); aspirin, indornethacin and phenylbutazone were purchased
from Sigma Chemical Company, St. Louis, MO.
Suprofen was either suspended in 0.5% rnethocel or solubiized in
water by the stoichiornetric addition of 1 N NaOH. In all cases, the
appropriate doses of compounds were calculated on the basis of their
respective free acid or base.
Results
Analgesic activity in the adjuvant arthritic rat. The
optimum time of vocalization subsequent to the initiation of
adjuvant arthritis in unprovoked animals is 16 to 18 days (Pircio
et a!., 1975). This time interval also coincides with the appear-
ance of established polyarthritic signs, most notably prominent
swelling of the hindpaws. Care was taken in these studies not
to include animals with ankylosed joints since the objective was
to measure the pain associated with flexion of an arthritic joint.
Table 1 presents the analgesic ED.o values and relative
potency ranking of suprofen and nine compounds as determined
by the vocalization response in adjuvant arthritic rats. For
comparative purposes, codeine and morphine were chosen as
representative narcotic analgesics. Sulindac and ibuprofen rep-
resented recently introduced NSAID. Proquazone (Gubler and
Baggiolini, 1978), difiunisal (Steelman et a!., 1978) and zome-
pirac sodium were chosen as new non-narcotic analgesics not
currently marketed in the U.S.A. The ED.o is defmed as that
dose which reduces the number of vocalizations by one-half
relative to vehicle control animals. For the determination of
relative potency values, suprofen was compared to each com-
pound by using a common slope. With the exception of mor-
phine, the regression lines for these drugs did not deviate
significantly from parallelism (Finney, 1971).
As can be seen from the data in table 1, suprofen is 50 times
more potent than acetaminophen and 5 times as potent as
codeine, while being 20 and 1.56 times less potent than mor-
phine (i.p.) and proquazone, respectively. Suprofen is statisti-
cally equipotent to sulindac, zomepirac, ibuprofen and diflunisal
in this test. Interestingly, indomethacin was inactive at 3 mg/
TABLE 1
Analgesic activity of suprofen and nine standard compounds in the
adjuvant-induced polyarthritic rat flexion test





Suprofen 98C 4.62 1.00
Codeine 44 22.68 0.20 (0.2, 0.87)”
Morphine 40 0.23e 20.00 (2.85, 1 25)d
Sulindac 40 1 .62 2.86 (0.36, 21.7)
Proquazone 39 2.96 1 .56 (2.0, 500)”
Acetaminophen 50 232.34 0.02 (0.005, 0.06)”
Zomepirac 47 1 .02 4.55 (0.25, 59)
Ibuprofen 58 1 1 .34 0.41 (0.08, 1.74)
Diflunisal 42 4.44 1 .04 (0.08, 6.8)
Indomethacin 1 0 >3.00
EDs and relative potencies were calculated by using a parallel line bioassay
(Finney, 1 964) with the common slopes of each compound’s dose-response data
compared with that of suprofen. A minimum of four doses was used to generate
each dose-response curve.
b Cl. . confidence interval.
C Pooled from two experiments.
d Statistically different from suprofen.
 Morphine was administered p. The slope of the curve was significantly
different from the suprofen slope. Therefore, the relative potency was not
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Fig. 2. Log dose response regression representing individual slopes of
four compounds in the adjuvant-induced hyperalgesic flexion test for
analgesic activity at 2 hr postdrug. Minimum of four doses used for
each regression line and nine rats per dose. None of the regression
lines deviated significantly from parallelism (Finney, 1971).
TABLE 2
30.0 100.0
I 8 Capetola et al. Vol. 214
Ill P < .05 compared to control value (modified t test, Cochran and Cox, 1960).
kg, a dose which far exceeds its anti-inflammatory dose in
adjuvant arthritic rats.
All the compounds tested, with the exception of acetamino-
phen, were capable of almost completely inhibiting the vocali-
zation response. However, codeine at 30 and 100 mg/kg and
morphine at 10 mg/kg had typical central nervous system
effects, whereas proquazone caused sedation and lethargy at a
dose of 30 mg/kg. Indomethacin was not tested at doses above
3 mg/kg.
Typical dose-response regression lines for suprofen and three
5
CONTROL
reference compounds are plotted in figure 2. The four non-
narcotic analgesics have statistically common slopes probably
indicating a common mechanism of action within this class of
compounds.
The onset ofaction ofsuprofen is rapid, progressively increas-
ing from 0.5 to 2 hr. Peak activity of suprofen was recorded at
2 hr. Table 2 presents an additional experiment showing a
comparison of suprofen and codeine with respect to their dose-
response and duration of action relationship. The peak effect of
codeine is seen at 1 Kr, the response declines rapidly and is
inactive at the end of 2 hr. In contrast, suprofen peaks at 2 hr
and at the highest dose significant analgesia is still apparent at
4 hr.
Naloxone antagonism. The ability of naloxone to reverse
the analgesic effect of morphine or suprofen was assessed in
polyarthritic rats (fig. 3). Naloxone (0.5 mg/kg) administered
s.c. in the nape of the neck had no effect when administered
alone. Morphine (3 mg/kg i.p.) caused a 68% inhibition of the
number of vocalizations measured at the time of peak activity
and this effect was completely reversed by naloxone. In con-
trast, naloxone had no effect upon the analgesic action of
suprofen measured at the time of peak activity.
Separation ofthe anti-inflammatory (antiedema) effect
from analgesic activity. Table 3 presents simultaneous mea-
surement of paw volume (by using a mercury plethysmograph)
and the number of vocalizations in adjuvant arthritic rats after
the oral administration of 10 mg/kg of suprofen. In the control
animals, there is a slight but insignificant decrease in paw
volume at 1 and 2 hr, but there is no decrease in the number of
vocalizations. Suprofen caused a significant and progressive
decline in the number of vocalizations, 1 and 2 hr postdrug,
while causing no significant decrease in paw volume.
Interaction of suprofen and acetaminophen in the ad-
juvant arthritic rat. Numerous clinical studies point out the
many possible interactions that occur between the NSAID and
the peripheral analgesics (Bulletin on the Rheumatic Diseases,
1977-78). For example, an investigation of indomethacin effi-
cacy in rheumatoid arthritis failed to find a drug-placebo dif-
Onset and duration of analgesic activity in the adjuvant arthritic rat after oral administration
(mean number of vocalizations ± S.E.M.)
COMPOUND n I Hr. 2 Hr. 3 Hr. 4 Hr. 5 Hr.
CONTROL 16 5.0±0.0 5.0±0.0 4.7±0.2 4.9±0.1 6.0±0.0
CODEINE-SO4
0.3 mg/kg 9 4.4±0.4 4.4±0.6 4.4±0.6 5.0±0.0 5.0±0.0
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expected to attenuate the writhing induced by AAP adminis-
Fig. 3 Failure of naloxone (NX) to block the anal-
gesic activity of suprofen in the rat adjuvant ar-
thritic flexion test. Each treatment group repre-
sents a minimum of 1 0 rats. The saline treatment
represents the controls for the i.p. administration
of morphine SO4 and the distilled water treatment
for suprofen (p.o.). Morphine was tested 1 hr post-
drug, suprofen 2 hr postdrug. In all groups, nal-
oxone HCI was administered s.c. 1 5 mm before
measurement of vocalization.
TABLE 3











0.05 ± 0.05 0.15 ± 0.06 5.0 ± 0.0 5.0 ± 0.0 5.0 ± 0.0
Suprofen 10 0.06 ± 0.04 0.14 ± 0.07 4.58 ± 0.28 3.42 ± 0.58 2.41 ± 0.54
. P < .05 (modified t test. Cochran and Cox, 1 960) compared to the distilled water control group).
a Suprofen was administered orally in distilled water as the sodium salt. The number of vocalizations was determined immediately after measuring the paw volume
by mercury plethysmography. Minimum of 1 2 rats per group.
ference when aspirin was allowed ad !ibitum during the course
ofthis study (Cooperating Clinics ofthe American Rheumatism
Association, 1967). Similar data have been demonstrated in the
adjuvant arthritic rat (Van Arman et a!., 1972). Accordingly,
the interaction of suprofen and acetaminophen was tested in
the adjuvant arthritic rat with an experimental design capable
of detecting additivity, antagonism or potentiation.
A total of thirty groups (8-10 rats per group) were used for
the entire experiment. Randomization was accomplished by
assigning each cage a number drawn from a box and the
experiment was done in a blind manner. Each dose-response
curve for acetaminophen (30, 60, 120 and 240 mg/kg p.o.) was
repeated in the presence of an increasing concentration of
suprofen (0.0, 0.3, 1, 3, 10 and 30 mg/kg p.o.) and ED,o values
were calculated for each dose-response curve interaction. In
these experiments, the criteria used for an effect were that if an
animal squeaked three or more times it was considered nonan-
algesic, two times or less, it was analgesic. The doses of acet-
aminophen and suprofen were plotted as rectangular coordi-
nates and an isobole (using ED,o values) was consthicted (fig.
4) with acetaminophen along the x-axis and suprofen values
along the y-axis. Most of the points were found lying below the
theoretical straight line joining the two points with the coordi-
nates. The straight line is defined as the line of additivity and
the hyperbola as potentiation. Statistical analysis (ScsI, 1974)
showed the experimental hyperbola to be significantly different
from linearity (P < .01). Thus, the data indicates that suprofen
and acetaminophen potentiate each other in this model.
Other analgesic assays. In the Randall-Selitto paw pres-
sure test in rats, suprofen raised the threshold of only the
inflamed paw (fig. 5) but had no effect on the normal paw. The
data shown are from 1 hr postdrug administration.
The centrally acting analgesic agent, morphine, was able to
raise the thresholds of both the normal and inflamed paws to
about 100% above control values. The other peripherally acting
analgesics, indomethacin, aspirin and phenylbutazone, raised
the threshold of only the inflamed paws. In the hyperalgesic
(inflamed) paw, suprofen was 7 times more potent than indo-
methacin, 142 times more potent than phenylbutazone, 238
times more potent than aspirin and equipotent to morphine,
i.e., within the 95% confidence interval.
AAP injected i.p. in mice produces a writhing syndrome
which is inhibited by narcotic analgesics and antagonists and
the peripherally acting analgesics (Collier et a!., 1968, 1973;
Helfner and Jaques, 1968, 1970; James and Church, 1978).
Recent evidence suggests that prostaglandins, formed from
exogenously administered AAP, are the causative agents in this
model of algesia (Collier et a!., 1973; Moncada and Vane, 1977).
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Fig. 4. Isobolograph of the analgesic interaction of suprofen and
acetaminophen in the adjuvant-induced hyperalgesic flexion test. Each
. represents an ED determination of the various combination
of doses and shows syngergy between acetaminophen and suprofen;








Fig. 5. Dose-response curves on the inflamed paw
of suprofen and four standards for analgesic activity
1 hr postdrug in the Randall-Selitto paw pressure
test in the rat. The potency ratios (95% confidence
interval) are shown in the upper right-hand corner.
Minimum 1 0 rats per dose.
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tration. Table 4 shows the oral ID,o values of suprofen and four
standard peripheral analgesics on AAP-induced writhing in
mice. The approximate order of potency is indomethacin >
suprofen > aspirin > phenylbutazone > acetaminophen.
Mydriatic activity in mice and the Eddy hot-plate assay (as
modified by Janssen and Jageneau, 1957) as well as the warm
water-induced tail withdrawal reflex in rats (Janssen et a!.,
1963) are assays capable of detecting narcotic analgesics. Oral
doses of suprofen up to 160 mg/kg were without effect on
increasing the hot-plate reaction time, pupil diameter in mice
or prolonging the tail reaction time in rats to warm water (C. J.
E. Niemegeers, personal communication).
Arachidonic acid cascade. The ability of suprofen to in-
hibit prostacyclin synthetase was determined by bioassay on
bovine coronary artery strips. The control response generated
by 200 ng of PGH2 and blood vessel microsomes was 6.2 ± 0.2
cm relaxation. Concentrations of suprofen ranging from 200 to
1000 .tg/ml failed to inhibit prostacydlin formation (6.3 cm). As
a positive control, 0.3 to 1.0 .tg/ml of 15-hydroperoxy-arachi-
domc acid was used and caused complete inhibition. At very
high doses of suprofen, (1500 tg/mi or higher) slight inhibition
was detectable, but was probably due to nonspecific effects.
Thromboxanes produce a rapid and profound contraction of
the isolated rabbit thoracic aorta strip. The control response
produced by the incubation of 200 ng of PGH2 plus the platelet
microsomes was 6.3 ± 0.8 cm contraction. Suprofen, at doses of
150 to 500 jg did not change the response (5.9 ± 1 cm, n = 5),
whereas 1000 and 1500 g produced a 60% inhibition. Imidazole,
a known inhibitor of thromboxane synthetase, inhibited the
platelet enzyme at concentrations of 50 to 200 tg/ml.
The antiprostaglandin effects were determined on strips of
rabbit aorta, bovine coronary artery, rat fundus and chicken
rectum by infusing suprofen at a rate of 0.1 ml/min into the
Krebs-Henseleit media before bathing the tissues. Final con-
centrations of suprofen at 3 to 50 jg/ml did not alter the
contractile response to directly applied PGE2 or PGH2 tested
at 50, 100 and 200 tg.
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TABLE 4
The oral inhibitory potency of suprofen and four other peripherally
acting analgesics on arachidonic acid-induced writhing
Treatment” Dose N/Nc % Inhibition  I.)
mg/kg mg/kg
vehicle control 22/3O
Suprofen 0.01 7/10 4.5
0.032 4/10 45.5 0.072




Acetaminophen 50 6/10 18.2
100 2/10 72.7 91.5
200 2/10 72.7 (80.8. 509)
300 1/10#{176} 86.4
Acetysalicylic 6.25 6/10 18.2
Acid 12.5 4/10 45.5 15.0
25.0 2/10#{176} 72.7 (10.0, 21.1)
50.0 1/10’ 86.4
Indomethacin 0.003 7/10 4.5
0.01 4/10 45.5
0.03 2/10’ 72.7 0.014




Phenylbutazone 20.0 5/10 31.8
40.0 2/10’ 72.7 28.3
80.0 1/10#{176} 86.4 (15.1, 131)
a Arachidonic acid (1 mg/kg) was dissolved in 0.9% NaCI containing a minimal
amount of 0.1 N NaOH (final pH - 7.4), perioxided by aeration for 5 mm and
administered p.
b Drugs in 0.5% methylcellulose were administered orally 60 mm before
arachidonic acid challenge.
C Number of mice writhing per number of mice tested. Mice were observed
from 2 to 1 5 mm after challenge.
d Data pooled from three experiments.
, Significantly different from control (P < .5, Fisher exact test, 1956).
The ability of suprofen to inhibit cyclo-oxygenase activity in
rabbit heart and kidney was determined on the basis that an
intracardiac or intrarenal injection of bradykinin (1 g) caused
the release into the cardiac and renal venous effluents of pros-
taglandin-like spasmogenic substances that contract rat stom-
ach and chick rectum strips. Bradykinin (1 tg) elicited a release
equivalent to 60 ± 20 ng of PGE2 from the heart and kidney,
whereas, exogenous arachidonate (10 tg) released 35 ± 15 ng of
PGE2 equivalents. Suprofen infused into the perfused heart or
kidney at 3, 5, or 10 zg/ml final concentration failed to alter the
amount of PG released by bradykinin or arachidonic acid (n =
6). However, at 50 zg/ml suprofen caused a 55% inhibition of
the conversion of exogenous arachidonate into PGE2, whereas
the blockade of bradykinin-induced prostaglandin release was
only 15% (n = 4). Bradykinin works by releasing endogenous
arachidonate which is more efficiently coupled to the cyclo-
oxygenase system than is exogenous arachidonate and would
therefore be expected to be more resistant to blockade. Indo-
methacin was used as a positive control and caused a 100%
inhibition of arachidonate- or bradykinin-induced PG release
by heart and kidney at 0.1 to .3 pg/mi final concentrations. This
minimal effect of suprofen on cyclo-oxygenase activity in these
two tissues was surprising in view of previous data that sug-
gested its mechanism of action was due to inhibition of pros-
taglandin biosynthesis (Janssen, 1975; Van Nueten et a!., 1976).
Therefore, a direct assessment of the ability of suprofen to
inhibit prostaglandin biosynthesis was determined from cyclo-
oxygenase activity in bovine seminal vesicles (table 5). The
approximate rank order of potency is suprofen > indomethacin
> naproxen > ibuprofen > phenylbutazone > sodium salicylate.
PGE is capable of dilating the renal vasculature and inhibi-
tom of PG synthesis, e.g., phenylbutazone has been reported to
decrease blood flow to the kidneys (Williamson et a!., 1978).
Studies were therefore conducted to determine the effect of
suprofen on renal artery blood flow in the anesthetized dog. For
comparative purposes, phenylbutazone was also studied. Table
6 shows that an i.v. infusion of suprofen (2 mg/kg) did not
significantly alter renal artery blood flow. Even at a higher i.v.
dose (10 mg/kg), suprofen had no significant effect on renal
blood flow (data not shown). In contrast, however, 2 mg/kg of
phenylbutazone reduced kidney blood flow by 21.4 ± 9.2 ml/
mm. These results are in agreement with the relative lack of
effect of suprofen on cyclo-oxygenase activity in isolated rabbit
kidney. These in vivo data, taken together with the in vitro
data presented above, suggest that suprofen may be a tissue
selective inhibitor cyclo-oxygenase activity.
Discussion
Animal models commonly employed to assay narcotic and
non-narcotic analgesics reqdire the use ofartificial provocations
such as heat, mechanical or chemical insult. The phenylquinone
writhing test in mice and the Randall-Selitto test in rats are
used extensively for the experimental evaluation of analgesic
agents and provide reasonable correlations to clinical efficacy
and potency. However, a variety of centrally and peripherally
acting nonanalgesic pharmacological agents are active in this
test and the Randall-Selitto test demonstrates a high degree of
variability. A major complaint of rheumatoid arthritic patients
is the pain associated with an affected joint. Adjuvant arthritis
in rats resembles the human condition with respect to both
inflammation and hyperalgesia upon joint movement. In this
regard, the adjuvant rat flexion test represents a unique model
of pathologically induced pain.
A variety of narcotic and non-narcotic analgesics are active
in the adjuvant rat flexion test (table 1) (Kuzuna and Kawai,
1975). There also seems to be a good correlation of potency in
this model with clinical potency as is also true with the model
of Pircio et a!. (1975) who used unprovoked adjuvant arthritic
rats in comparative potency assays. By using the flexion test
described here, suprofen was shown to be more potent than
codeine and acetaminophen, equipotent to sulindac, diflunisal,
zomepirac and ibuprofen and less potent than morphine and
proquazone. Suprofen is characterized as having a rapid onset
of action, i.e., progressively increasing from 0.5 to 2 hr with
analgesic activity still evident at 4 hr after oral administration.
The analgesic potency of suprofen was also demonstrated vs.
TABLE 5
Activity of suprofen and five standards on prostaglandin
biosynthesis from bovine seminal vesicles
Compound Mean lC ± S.E.M.’
M
Suprofen 1.82 ± 0.18
Indomethacin 3.16 ± 0.42
Naproxen 14.42 ± 2.03
Ibuprofen 45.20 ± 2.44
Phenylbutazone 1 69.00 ± 13.64
Sodium salicylate” 31 30 ± 328.50
a Mean lC value from five replicate experiments.
b Acetylsalicylic acid was solubilized by the stoichimetric addition of 1 N
NaOH. The product was assumed to be sodium salicylate.
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TABLE 6
Effect of suprofen or phenylbutazone on renal artery blood flow in the anesthetized dog
Mean Change in Renal
Treatment Dose








2 -10.2 ± 6.4
mi/mm
-31.6 ± 12.9 -
mI/mm
21.4 ± 9.2a
Suprofen 2 -18.0 ± 9.5 -23.6 ± 4.3 - 5.6 ± 9.6”
a Statistically different from vehicle control (P < .05) N 5.
b Not significantly dlfterent from vehicle control value (P > .05) N = 5.
arachidonate-induced writhing and in the Randall-Selitto test
where it was equipotent to parenteral morphine (table 4; fig. 5).
Many of the interactions which have major clinical signifi-
cance in medicine occur with drugs that are used in the treat-
ment of rheumatic diseases (Bulletin on the Rheumatic Dis-
eases, 1977-1978). Experimentally, Van Arman et al. (1972)
found antagonism at some doses of the anti-inflammatory ef-
fects of indomethacin and of aspirin in the adjuvant arthritic
rat. Therefore, the data in the present report concerning the
interaction potential of suprofen and acetaminophen are im-
portant because not only was antagonism absent but potentia-
tion occurred. The mechanism of this interaction remains un-
clear at the present time. Clinical trials with these combinations
wifi determine their overall importance.
Several lines of evidence support the conclusion that suprofen
is not a narcotic analgesic. Firstly, its analgesic effects in the
adjuvant rat flexion test were not blocked by naloxone at doses
which completely block the analgesic effects of morphine. See-
ondly, in the Randall-Selitto test, suprofen raised the threshold
of the inflamed paw but had no effect on the threshold of the
normal paw, as did morphine. Thirdly, suprofen was without
effect on the warm water tail-withdrawal reflex, a sensitive
assay capable of detecting narcotic analgesic drugs. Lastly, at
doses of 160 mg/kg, suprofen was inactive in the hot-plate test
and failed to increase pupil diameter in mice. Clearly, suprofen
evokes an analgesic effect at some site and by a different
mechanism than that of the narcotics.
Vane (1973) was the first to propose that tissue selective
inhibition of prostaglandin biosynthesis may exist within the
family of aspirin-like compounds and that this could be respon-
sible for the observed variations in their ability to generate
various metabolites of arachidonic acid. Thus, tissue selective
inhibition of prostaglandin synthetases may be related not only
to differential drug distribution or to specificity toward different
multiple molecular forms of the prostaglandin generating sys-
tem but possibly to different metabolites as well. Several lines
ofevidence, both direct and indirect, suggest that these selective
effects may also explain the dissociation of analgesic and anti-
inflammatory properties reported for a variety of NSAID and
shown in the present study for suprofen.
Previous data indicated that suprofen was a potent inhibitor
of arachidonic acid hydroperoxide-induced contraction of the
guinea-pig ileum and rat fundic strips (Van Nueten et a!., 1976).
Human, guinea pig and dog platelet aggregation induced by
various agents both in vivo and in vitro was also inhibited by
very low doses of suprofen (De Clerck et a!., 1975). In addition,
delay of castor oil diarrhea in rats is another method used to
evaluate inhibitors of prostaglandin biosynthesis (Awouters et
a!., 1978). In this assay, the activity pattern of suprofen was
consistent with that of a very potent, short-acting inhibitor of
prostaglandin biosynthesis. Data in the present report show
suprofen to be a potent inhibitor when tested against both
AAP-induced writhing in mice and prostaglandin biosynthesis
from bovine seminal vesicles (tables 4 and 5). In contrast,
suprofen was shown to be a weak inhibitor of cyclo-oxygenase
activity measured from rabbit heart and kidney (P. Needleman,
personal communication). In vivo confirmation of these data in
another species, the dog, was demonstrated by the lack of effect
of suprofen on renal blood flow (table 6). Decreased renal blood
flow, induced by inhibitors of prostaglandin biosynthesis such
as meclofenamate and phenylbutazone, has been demonstrated
in several species (Williamson et a!., 1978; Chrysant et a!., 1978;
Aiken and Vane, 1973). Suprofen thus appears to have differ-
ential effects on the synthesis of prostaglandins in a variety of
tissues. Acetaminophen may be another example ofa compound
with specificity toward prostaglandin production. Vane (1973)
interpreted the experiments ofLim et a!. (1964) on the analgesic
effects of acetaminophen on bradykinin-induced vocalization in
the dog to mean that prostaglandin production in nervous tissue
has a greater sensitivity to acetaminophen.
Hyperalgesia, a state in which a previously inadequate me-
chanical or chemical stimulus can result in a pain response, is
a unique phenomenon produced by prostaglandins. Although
there is abundant evidence that prostaglandins contribute to
and may modulate the inflammatory process, analgesic doses
of aspirin and related compounds given in the Randall-Selitto
assay are not accompanied by a significant antiedema action
(Gilfoil et a!., 1963). Suprofen exhibits a similar profile of
activity in that a dose of more than twice the analgesic ED,,,
causes significant pain relief in adjuvant arthritic rats with no
simultaneous effect on attendant paw volume. Conversely,
prednisone, an anti-inflammatory steroid, caused only a mini-
mal analgesic effect at doses up to 20 mg/kg in this model
(Kuzuna and Kawai, 1975). Latranyi and Taber (1979), using
the carrageenan-inflamed paw test, showed that parachloro-
phenylalanine, an inhibitor of serotonin biosynthesis, antago-
nized the analgesic but not the anti-inflammatory action of
clonixin, a non-narcotic agent, in the same animals. Their data
suggest that after exposure to a phlogistic stimulus, activation
of the arachidomc acid cascade can occur both in the cellular
and neural compartments, and it is reasonable, therefore, to
suggest that compounds can inhibit one or the other, or both.
Additionally, the aminophenaquine derivatives, glafenine and
floctafenine, are potent analgesics and inhibitors of prostaglan-
din biosynthesis but are relatively weak anti-inflammatory
agents (Deraedt et a!., 1976).
The prostaglandins producing hyperalgesia in the adjuvant
arthritic rat must be relatively short-lived because suprofen
causes significant pain relief within 1 hr and has no capacity to
block prostaglandin receptors. Ferreira (1978b) showed kinetic
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differences between the hyperalgesic effects of prostacycin and
PGE2 in the rat paw and dog knee joint. As an alternative
explanation, part of the analgesic effects of the peripheral
analgesics may occur through a central non-narcotic action as
suggested by Ferriera, 1978a. Although the total mechanism of
action of suprofen cannot be determined on the basis of the
present experiments, the data are consistent with the hypoth-
esis that suprofen and other peripheral analgesics have anal-
gesic activity independent from their anti-inflammatory effects.
In SUmmary, in a series of tests designed to demonstrate
antinociceptive properties of peripheral analgesics, suprofen
was a potent, orally effective, non-narcotic analgesic demon-
strating some specificity on prostaglandin biosynthetic path-
ways. Clinical studies are now in progress.
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